Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03378-2 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Advances in Therapy, 2025. Verfasst von Martin Desrosiers und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head and Neck Surgery, University of Montreal, Quebec, Canada. desrosiers_martin@hotmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Obstruction, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
INTRODUCTION: Nasal congestion/obstruction (NC) contributes to the high disease burden in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patient perception of NC may not accurately reflect nasal patency, while peak nasal inspiratory flow (PNIF) is an objective method with established thresholds for normal nasal airflow. This analysis evaluated the association between NC and PNIF and the impact of baseline PNIF on dupilumab efficacy in patients with severe CRSwNP. METHODS: This was a post hoc analysis of patients treated with placebo or dupilumab 300 mg every 2 weeks in the SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) phase III studies. Patients provided daily e-diary measures of PNIF (L/min) using PNIF meters, and NC by patient-reported evaluation of severity (scored 0-3). Other assessed outcomes were nasal polyp score (NPS), 22-item Sinonasal Outcome Test (SNOT-22), loss of smell (LoS), University of Pennsylvania Smell Identification Test (UPSIT), and Lund-Mackay computed tomography. Outcomes were assessed in two subgroups: baseline PNIF < 120 L/min and ≥ 120 L/min. RESULTS: Of 724 patients, 552 (76%) had PNIF < 120 L/min and 172 (24%) had PNIF ≥ 120 L/min at baseline. The PNIF < 120 L/min subgroup had higher mean scores for NPS and SNOT-22 and more smell impairment (LoS and UPSIT). PNIF weakly correlated with NC at baseline (Spearman coefficient - 0.348 [95% CI - 0.410, - 0.282], P < 0.0001). Correlations between change from baseline in PNIF and NC at week 24 were weak in the dupilumab group (- 0.390 [- 0.468, - 0.305], P < 0.0001) and moderate in the placebo group (- 0.497 [- 0.582, - 0.399], P < 0.0001). CONCLUSION: These results confirm PNIF as a valuable method for assessing nasal obstruction in patients with severe CRSwNP. The degree of nasal flow impairment at baseline does not impact dupilumab's efficacy. A graphical abstract and video abstract are available for this article. Chronic rhinosinusitis with nasal polyps (CRSwNP) causes narrowing, and sometimes complete blockage, of the air passages in the nose, making it difficult to breathe. This can impact a person’s ability to smell, taste, sleep, and perform daily activities, which in turn negatively impacts their overall quality of life. Measures of nasal congestion and loss of smell rely on people’s self-perceptions, which can vary and may not reflect the actual level of congestion seen when cameras are inserted into the nose. This article looks at a measure of nasal airflow called peak nasal inspiratory flow (PNIF), a non-invasive method for directly measuring airflow through the nose, and how this compares with the patient-reported measures nasal congestion and loss of smell. Data from two studies (SINUS-24 and SINUS-52) assessing the effects of a drug called dupilumab in people with severe CRSwNP were used. Patients were grouped according to their PNIF scores at recruitment (a PNIF measure of less than 120 L per minute indicated poor nasal airflow). Results showed a relationship between low PNIF and severe nasal congestion and loss of smell, suggesting PNIF may be a useful and convenient method for directly assessing nasal airflow. The study also shows that dupilumab was effective for patients with severe CRSwNP regardless of nasal airflow quality at the beginning of the studies. Video Abstract (MP4 157916 KB).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Otolaryngology-Head and Neck Surgery, University of Montreal, Quebec, Canada. desrosiers_martin@hotmail.com.
- Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Brigham and Women's Hospital, Division of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.
- Otorhinolaryngology-Head and Neck Surgery, A. Gemelli Hospital Foundation IRCCS, Rome, Italy.
- Sanofi, Bridgewater, NJ, USA.
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Desrosiers, M., Nash, S., Lane, A., Lee, S. E., De Corso, E., Xia, C., Corbett, M., Radwan, A., Rowe, P. J., & Deniz, Y. (2025). Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies. Advances in Therapy. https://doi.org/10.1007/s12325-025-03378-2
Vancouver
Desrosiers M, Nash S, Lane A, Lee SE, De Corso E, Xia C, et al. Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies. Advances in Therapy. 2025. doi:10.1007/s12325-025-03378-2
BibTeX
@article{Desrosiers2025,
author = {Desrosiers, Martin and Nash, Scott and Lane, Andrew and Lee, Stella E and De Corso, Eugenio and Xia, Changming and Corbett, Mark and Radwan, Amr and Rowe, Paul J and Deniz, Yamo},
title = {Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03378-2}
}
EUVIMED